← Back to Patent Explorer
US4064235A Expired / Lapsed US ⏱️ 0.0 years remaining

Dopamine derivative compounds, preparation thereof and medicine containing same

Assignee: Eisai Co Ltd
•
Filing: 1976-08-17
•
Granted: 1977-12-20
•
Expires: 1996-08-17
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A novel dopamine derivative compound having the following general formula and pharmacologically acceptable acid addition salt thereof: ##STR1## wherein X stands for a di- or tri-peptide residue derived from alanine, glycine, glutamine, isoleucine, lysine, leucine, tyrosine proline or valine, having an excellent activity of increasing the renal blood flow are provided.

Inventors

  • 👤 Noboru Yanaihara
  • 👤 Toshiji Igarashi
  • 👤 Youichi Kunii

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-27 07:09
CPC Classifications
C; C07; C07K; C07K5/00; C07K5/04; C07K5/06; C07K5/06008; C07K5/06017; C07K5/06034; C07K5/06026; C07K5/06052; A; A61; A61K; A61K38/00

Claims Analysis

Total Claims: 16
Claim 1
Independent Claim 34 words
A compound having the formula: ##STR8## wherein X is a di- or tri-peptide residue derived from alanine, glycine, glutamine, isoleucine, lysine, leucine, tyrosine, proline or valine, or a pharmacologically acceptable acid addition salt thereof.
Claim 2
Dependent Claim 34 words
A compound having the formula: ##STR8## wherein X is a di- or tri-peptide residue derived from alanine, glycine, glutamine, isoleucine, lysine, leucine, tyrosine, proline or valine, or a pharmacologically acceptable acid addition salt thereof.
Claim 3
Dependent Claim 15 words
A compound as claimed in claim 1 wherein the group ##STR9## is a glycyl-L-prolyl group.
Claim 4
Dependent Claim 15 words
A compound as claimed in claim 1 wherein the group ##STR10## is a L-isoleucylvalyl group.
Claim 5
Dependent Claim 15 words
A compound as claimed in claim 1 wherein the group ##STR11## is a glycyl-L-glutamyl group.
Claim 6
Dependent Claim 15 words
A compound as claimed in claim 1 wherein the group ##STR12## is a glycylglycyl-L-Leucyl group.
Claim 7
Dependent Claim 15 words
A compound as claimed in claim 1 wherein the group ##STR13## is a glycylglycyl-L-prolyl group.
Claim 8
Independent Claim 60 words
A method of increasing the renal blood flow rate in a subject requiring such treament, which comprises: administering to such subject a therapeutically effective amount of a compound having the formula: ##STR14## wherein X is a di- or tri-peptide residue derived from alanine, glycine, glutamine, isoleucine, lysine, leucine, tyrosine, proline or valine, or a pharmacologically acceptable acid addition salt thereof.
Claim 9
Independent Claim 60 words
A method of increasing the renal blood flow rate in a subject requiring such treament, which comprises: administering to such subject a therapeutically effective amount of a compound having the formula: ##STR14## wherein X is a di- or tri-peptide residue derived from alanine, glycine, glutamine, isoleucine, lysine, leucine, tyrosine, proline or valine, or a pharmacologically acceptable acid addition salt thereof.
Claim 10
Dependent Claim 15 words
A method as claimed in claim 7 wherein the group ##STR15## is a glycyl-L-prolyl group.
Claim 11
Dependent Claim 15 words
A method as claimed in claim 7 wherein the group ##STR16## is an L-isoleucylvalyl group.
Claim 12
Dependent Claim 15 words
A method as claimed in claim 7 wherein the group ##STR17## is a glycyl-L-glutamyl group.
Claim 13
Dependent Claim 15 words
A method as claimed in claim 7 wherein the group ##STR18## is a glycylglycyl-L-leucyl group.
Claim 14
Dependent Claim 15 words
A method as claimed in claim 7 wherein the group ##STR19## is a glycylglycyl-L-prolyl group.
Claim 15
Dependent Claim 18 words
A method according to claim 7 in which said compound is administered in combination with a pharmaceutical carrier.
Claim 16
Dependent Claim 23 words
A method according to claim 7 in which the compound is administered in an amount of from 10 to 500 mg per day.

References Cited (Backward Citations)

US3803120A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1980-12-19 1981-06-20 1981-12-20 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1984-12-19 1985-06-20 1985-12-20 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1988-12-19 1989-06-20 1989-12-20 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag